SSE Ticker: 688189

Hunan Nucien Pharmaceutical Co., Ltd.

南新制药

Authorized Representative: 杨文逊

Board: Star Market

Industry Classification: Biomedicine

Justify the volatility of the company's performance? Nanxin Pharmaceutical's reply to the annual report inquiry letter

Post date May 16, 2022 — 09:59 Post Lock

Nanxin Pharmaceutical lost 167 million in the following year, IPO raised 1.2 billion Western Securities sponsored wealth management channel Rongyi Information Network

Post date May 6, 2022 — 11:36 Post Lock

Nanxin Pharmaceutical disclosed that it achieved revenue of 197 million yuan in the first quarter of 2022 Teller Report

Post date May 5, 2022 — 11:09 Post Lock

Nanxin Pharmaceutical: The total amount of external guarantees of the company and its holding subsidiaries is about 365 million yuan

Post date April 30, 2022 — 11:21 Post Lock

Nanxin Pharmaceutical: Net profit in 2021 is about -167 million yuan

Post date April 30, 2022 — 11:21 Post Lock

Hunan Nanxin Pharmaceutical Co., Ltd. Announcement on Resolutions of the First Extraordinary General Meeting of Shareholders in 2022

Post date April 9, 2022 — 10:00 Post Lock